{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[92mðŸŒŠ SUCCESS: connected successfully to 192.168.2.69\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "from magnet.ize import memory\n",
    "config = {\n",
    "    \"MILVUS_URI\": \"192.168.2.69\"\n",
    "    , \"DIMENSION\": 1024\n",
    "    , \"MODEL\": \"BAAI/bge-large-en-v1.5\"\n",
    "    , \"INDEX\": \"test_collection\"\n",
    "    , \"INDEX_PARAMS\": {\n",
    "        'metric_type': 'COSINE',\n",
    "        'index_type':'HNSW',\n",
    "        'params': {\n",
    "            \"efConstruction\": 40\n",
    "            , \"M\": 48\n",
    "        },\n",
    "    }\n",
    "}\n",
    "\n",
    "index = memory.Embedder(config)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ownershipDocument: schemaVersion: X0508documentType: 4periodOfReport: 20231013notSubjectToSection16: 0issuer: issuerCik: 0001037676issuerName: ARCH RESOURCES, INC.issuerTradingSymbol: ARCHreportingOwner: reportingOwnerId: rptOwnerCik: 0001809723rptOwnerName: Giljum Matthew C.reportingOwnerAddress: rptOwnerStreet1: ONE CITYPLACE DRIVErptOwnerStreet2: SUITE 300rptOwnerCity: ST. LOUISrptOwnerState: MOrptOwnerZipCode: 63141reportingOwnerRelationship: isDirector: 0isOfficer: 1isTenPercentOwner: 0isOther: 0officerTitle: Sr. VP and CFOaff10b5One: 1nonDerivativeTable: nonDerivativeTransaction: securityTitle: value: Common StocktransactionDate: value: 20231013transactionCoding: transactionFormType: 4transactionCode: MequitySwapInvolved: 0transactionTimeliness: trans\n",
      "4 - Giljum Matthew C. (0001809723) (Reporting)_doc4\n",
      "rossUnrealizedLossBeforeTaxCurrent: 0AvailableForSaleSecuritiesDebtSecuritiesCurrent: 1493000DebtSecuritiesAvailableForSaleAmortizedCostCurrent: 7963000AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent: 0AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax: 0AvailableForSaleSecuritiesDebtSecuritiesNoncurrent: 7964000DebtSecuritiesAvailableForSaleAmortizedCostCurrent: 9456000AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent: 1000AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent: 0AvailableForSaleSecuritiesDebtSecuritiesCurrent: 9457000DebtSecuritiesAvailableForSaleAmortizedCostCurrent: 22549000AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxC\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "yinfact forLatondra NewtonsignatureDate: 20230926\n",
      "4 - Newton Latondra (0001983540) (Reporting)_wk-form4_1695763702\n",
      "ï»¿ EX312 3 ex_563898htm EXHIBIT 312 ex_563898htm Exhibit 312 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULES 13a14(a) AND 15d14(a), AS ADOPTED PURSUANT TO SECTION302 OF THE SARBANESOXLEY ACT OF2002 I, York A Ragen, certify that: 1 I have reviewed this quarterly report on Form10Q of Generac Holdings Inc; 2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in al\n",
      "10-Q - GENERAC HOLDINGS INC. (0001474735) (Filer)_ex_563898\n",
      "ï»¿ownershipDocument: schemaVersion: X0508documentType: 4periodOfReport: 20231102notSubjectToSection16: 0issuer: issuerCik: 0001818874issuerName: SoFi Technologies, IncissuerTradingSymbol: SOFIreportingOwner: reportingOwnerId: rptOwnerCik: 0001605786rptOwnerName: Borton Chad MreportingOwnerAddress: rptOwnerStreet1: C/O SOFI TECHNOLOGIES, INCrptOwnerStreet2: 234 1ST STREETrptOwnerCity: SAN FRANCISCOrptOwnerState: CArptOwnerZipCode: 94105reportingOwnerRelationship: isDirector: 0isOfficer: 1isTenPercentOwner: 0isOther: 0officerTitle: President SoFi Bankaff10b5One: 0nonDerivativeTable: nonDerivativeTransaction: securityTitle: value: Common StocktransactionDate: value: 20231102transactionCoding: transactionFormType: 4transactionCode: SequitySwapInvolved: 0transacti\n",
      "4 - SoFi Technologies, Inc. (0001818874) (Issuer)_wk-form4_1699316590\n",
      "erson including under certain circumstances following a change in control of the IssuerownerSignature: signatureName: /s/ Lisa Yun, AttorneyinfactsignatureDate: 20230919\n",
      "4 - DOCUSIGN, INC. (0001261333) (Issuer)_wk-form4_1695160015\n",
      "cePerShare: value: 158transactionAcquiredDisposedCode: value: ApostTransactionAmounts: sharesOwnedFollowingTransaction: value: 12322ownershipNature: directOrIndirectOwnership: value: DownerSignature: signatureName: /s/ F M Reuter as AttorneyinFact for Ernest W Marshall, JrsignatureDate: 20231005\n",
      "4 - MARSHALL ERNEST W JR (0001768444) (Reporting)_form4\n",
      "sting party with full information regarding the number of shares and prices at which the transaction was effectedownerSignature: signatureName: /s/ Daniel A Hudson as Power of AttorneysignatureDate: 20230907\n",
      "4 - Darling David E (0001488598) (Reporting)_rdgdoc\n",
      "549000AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent: 0AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent: 0AvailableForSaleSecuritiesDebtSecuritiesCurrent: 22549000DebtSecuritiesAvailableForSaleAmortizedCostCurrent: 10817000AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent: 1000AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent: 21000AvailableForSaleSecuritiesDebtSecuritiesCurrent: 10797000DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent: 18023000AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax: 0AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax: 221000AvailableForSaleSecuritiesDebtSecuritiesNoncurrent: 1\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "ï»¿ownershipDocument: schemaVersion: X0508documentType: 4periodOfReport: 20230915notSubjectToSection16: 0issuer: issuerCik: 0001261333issuerName: DOCUSIGN, INC.issuerTradingSymbol: DOCUreportingOwner: reportingOwnerId: rptOwnerCik: 0001796825rptOwnerName: GRAYSON BLAKE JEFFREYreportingOwnerAddress: rptOwnerStreet1: C/O DOCUSIGN, INC.rptOwnerStreet2: 221 MAIN STREET, SUITE 1550rptOwnerCity: SAN FRANCISCOrptOwnerState: CArptOwnerZipCode: 94105reportingOwnerRelationship: isDirector: 0isOfficer: 1isTenPercentOwner: 0isOther: 0officerTitle: Chief Financial Officeraff10b5One: 0nonDerivativeTable: nonDerivativeTransaction: securityTitle: value: Common StocktransactionDate: value: 20230915transactionCoding: transactionFormType: 4transactionCode: MequitySwapInvolved: 0\n",
      "4 - DOCUSIGN, INC. (0001261333) (Issuer)_wk-form4_1695160015\n",
      "ï»¿ownershipDocument: schemaVersion: X0508documentType: 4periodOfReport: 20230905issuer: issuerCik: 0000098222issuerName: TIDEWATER INCissuerTradingSymbol: TDWreportingOwner: reportingOwnerId: rptOwnerCik: 0001488598rptOwnerName: Darling David EreportingOwnerAddress: rptOwnerStreet1: C/O TIDEWATER INCrptOwnerStreet2: 842 W SAM HOUSTON PKWY N, STE 400rptOwnerCity: HOUSTONrptOwnerState: TXrptOwnerZipCode: 77024reportingOwnerRelationship: isOfficer: 1officerTitle: EVP, COOaff10b5One: 0nonDerivativeTable: nonDerivativeTransaction: securityTitle: value: Common StocktransactionDate: value: 20230905transactionCoding: transactionFormType: 4transactionCode: SequitySwapInvolved: 0transactionAmounts: transactionShares: value: 250transactionPricePerShare: value: 6841trans\n",
      "4 - Darling David E (0001488598) (Reporting)_rdgdoc\n",
      "ï»¿ EX32B 33 ex32bpso20233qhtm EX32B Document Exhibit 32(b) This Certification is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that sectionThis Certification shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as otherwise stated in such filing Certification Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code In connection with the Quarterly Report of Public Service Company of Oklahoma (the Company) on Form 10Q (the Report) for the quarter ended September30, 2023 as filed with the Securities and Exchange Commission on the date hereof,\n",
      "10-Q - AMERICAN ELECTRIC POWER CO INC (0000004904) (Filer)_ex32bpso20233q\n",
      "ï»¿ownershipDocument: schemaVersion: X0508documentType: 4periodOfReport: 20231013issuer: issuerCik: 0001679273issuerName: Lamb Weston Holdings, IncissuerTradingSymbol: LWreportingOwner: reportingOwnerId: rptOwnerCik: 0001187349rptOwnerName: JURGENSEN WILLIAM GreportingOwnerAddress: rptOwnerStreet1: C/O LAMB WESTON HOLDINGS, INCrptOwnerStreet2: 599 S RIVERSHORE LANErptOwnerCity: EAGLErptOwnerState: IDrptOwnerZipCode: 83616reportingOwnerRelationship: isDirector: trueisOfficer: falseisTenPercentOwner: falseisOther: falseaff10b5One: 0nonDerivativeTable: nonDerivativeTransaction: securityTitle: value: Common StocktransactionDate: value: 20231013transactionCoding: transactionFormType: 4transactionCode: AequitySwapInvolved: 0transactionAmounts: transactionShares: val\n",
      "4 - Lamb Weston Holdings, Inc. (0001679273) (Issuer)_form4-10172023_121045\n",
      "ï»¿ownershipDocument: schemaVersion: X0508documentType: 4periodOfReport: 20231004issuer: issuerCik: 0000763532issuerName: LSI INDUSTRIES INCissuerTradingSymbol: LYTSreportingOwner: reportingOwnerId: rptOwnerCik: 0001768444rptOwnerName: MARSHALL ERNEST W JRreportingOwnerAddress: rptOwnerStreet1: 10000 ALLIANCE RDrptOwnerCity: CINCINNATIrptOwnerState: OHrptOwnerZipCode: 45242reportingOwnerRelationship: isDirector: trueaff10b5One: falsenonDerivativeTable: nonDerivativeTransaction: securityTitle: value: Common SharestransactionDate: value: 20231004transactionCoding: transactionFormType: 4transactionCode: AequitySwapInvolved: 0transactionAmounts: transactionShares: value: 1187transactionPricePerShare: value: 158transactionAcquiredDisposedCode: value: ApostTransacti\n",
      "4 - MARSHALL ERNEST W JR (0001768444) (Reporting)_form4\n",
      "identifier: 0001824893segment: explicitMember: usgaap:GeneralAndAdministrativeExpenseMemberperiod: startDate: 20230101endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: srzn:UCSFLicenseAndOptionAgreementsMemberperiod: startDate: 20230101endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:FairValueInputsLevel2MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:RetainedEarningsMemberperiod: instant: 20230630context: entity: identifier: 0001824893segment: explicitMember: srt:MinimumMemberexplicitMember: srzn:PIPEWarrantsMemberperiod: startDate: 20230101endDate: 20230930context: entity: ide\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "ï»¿ownershipDocument: schemaVersion: X0206documentType: 3periodOfReport: 20231001noSecuritiesOwned: 1issuer: issuerCik: 0001851657issuerName: Vaxxinity, Inc.issuerTradingSymbol: VAXXreportingOwner: reportingOwnerId: rptOwnerCik: 0001579629rptOwnerName: Ray SumitareportingOwnerAddress: rptOwnerStreet1: 505 ODYSSEY WAYrptOwnerCity: MERRITT ISLANDrptOwnerState: FLrptOwnerZipCode: 32953reportingOwnerRelationship: isOfficer: 1officerTitle: Chief Legal Officer, SecretaryownerSignature: signatureName: /s/ Sumita RaysignatureDate: 20231011\n",
      "3 - Ray Sumita (0001579629) (Reporting)_rdgdoc\n",
      "ï»¿ownershipDocument: schemaVersion: X0508documentType: 4periodOfReport: 20231114notSubjectToSection16: 0issuer: issuerCik: 0000936528issuerName: WAFD INCissuerTradingSymbol: WAFDreportingOwner: reportingOwnerId: rptOwnerCik: 0001789995rptOwnerName: Mauer RyanreportingOwnerAddress: rptOwnerStreet1: 425 PIKE STREETrptOwnerCity: SEATTLErptOwnerState: WArptOwnerZipCode: 98101reportingOwnerRelationship: isDirector: 0isOfficer: 1isTenPercentOwner: 0isOther: 0officerTitle: EVP & Chief Credit Officeraff10b5One: 0nonDerivativeTable: nonDerivativeTransaction: securityTitle: value: Common StocktransactionDate: value: 20231114transactionCoding: transactionFormType: 4transactionCode: AequitySwapInvolved: 0transactionAmounts: transactionShares: value: 22973transactionPrice\n",
      "4 - WAFD INC (0000936528) (Issuer)_wk-form4_1700171914\n",
      "Insurance, Incstreet2: 1500 Solana Blvd, Bldg 4, Suite 4500city: WestlakestateOrCountry: TXzipCode: 76262securitiesClassTitle: Class A CommonsaleDate: 09/01/2023amountOfSecuritiesSold: 10000grossProceeds: 70702439remarks: The shares filed today will be sold by the Lindy Langston Spousal Lifetime Access Trust, Lindy Langston as TrusteenoticeSignature: noticeDate: 11/28/2023signature: /s/ JP Morgan Securities LLC as agent and attorneyinfact for Lindy Langston Spousal Lifetime Access Trust\n",
      "144 - Lindy Langston Spousal Lifetime Access Trust (0001850722) (Reporting)_primary_doc\n",
      " the Issuer, upon request, full information regarding the number of shares disposed of at each separate price within the price range noted aboveownerSignature: signatureName: /s/ Deanna M Smith, AttorneyinFactsignatureDate: 20231106\n",
      "4 - SoFi Technologies, Inc. (0001818874) (Issuer)_wk-form4_1699316590\n",
      " date of the first annual meeting of Lamb Weston's stockholders occurring after the date of grant, or earlier upon certain eventsownerSignature: signatureName: /s/ Eryk J Spytek by Power of Attorney from WG JurgensensignatureDate: 20231017\n",
      "4 - Lamb Weston Holdings, Inc. (0001679273) (Issuer)_form4-10172023_121045\n",
      "023 as filed with the Securities and Exchange Commission on the date hereof, I, Charles E Zebula, the chief financial officer of the Company certify pursuant to 18 USC Section 1350, as adopted pursuant to Section 906 of the SarbanesOxley Act of 2002 that, based on my knowledge (i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company /s/ Charles E Zebula Charles E Zebula Chief Financial Officer November2, 2023 A signed original of this written statement required by Section 906 has been provided to Public Service Company of Oklahoma and will be re\n",
      "10-Q - AMERICAN ELECTRIC POWER CO INC (0000004904) (Filer)_ex32bpso20233q\n",
      "ï»¿ EX9903 4 ex99_03htm CORPORATE PRESENTATION BY THE COMPANY FOR SEPTEMBER 2023 T onix Pharmaceuticals Holding Corp 8K Exhibit9903 2023 Tonix Pharmaceuticals Holding Corp TNX 102 SL FOR LONG COVID RESULTS OF THE TNX CY PA201 PREVAIL TRIAL BRIEFING DECK Version P0487 September 20, 2023 (Doc 1319 ) 2 2023 Tonix Pharmaceuticals Holding Corp Pipeline: Key Clinical Development Programs Status/Next Milestone Indication Candidates* Mid Phase 3 enrollment complete Phase 2 Topline Data Announced 5 Sept 2023 Fibromyalgia (FM) Long COVID (PASC 2 ) TNX 102 SL 1 Mid Phase 2, Targeted 3Q 2023 Start Cocaine Intoxication FDA Breakthrough Designation TNX 1300 3 Phase 2 enrollment complete 5 Prevention of Chronic Migraine TNX 1900 4 Phase 2 enrollment complete 6 Major Depressi\n",
      "8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)_ex99_03\n",
      "0001824893segment: explicitMember: usgaap:CommonStockMemberperiod: instant: 20220930context: entity: identifier: 0001824893segment: explicitMember: usgaap:CommonStockMemberperiod: instant: 20230331context: entity: identifier: 0001824893segment: explicitMember: srzn:PublicWarrantsMemberexplicitMember: usgaap:FairValueInputsLevel2MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:AdditionalPaidInCapitalMemberperiod: instant: 20230630context: entity: identifier: 0001824893period: startDate: 20220101endDate: 20220930context: entity: identifier: 0001824893segment: explicitMember: usgaap:RetainedEarningsMemberperiod: instant: 20230331context: entity: ident\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "egment: explicitMember: usgaap:RetainedEarningsMemberperiod: instant: 20211231context: entity: identifier: 0001824893segment: explicitMember: usgaap:RetainedEarningsMemberperiod: startDate: 20230101endDate: 20230331context: entity: identifier: 0001824893segment: explicitMember: srzn:PublicWarrantsMemberexplicitMember: usgaap:FairValueInputsLevel1MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: srzn:PublicWarrantsMemberexplicitMember: srzn:CommonStock1Memberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: srzn:CorporateBondMemberexplicitMember: usgaap:FairValueInputsLevel1MemberexplicitMember: usgaap:FairValueMeasure\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "ontained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company /s/ Mark Eubanks Mark Eubanks President and Chief Executive Officer (Principal Executive Officer) November7, 2023 A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request\n",
      "10-Q - BRINKS CO (0000078890) (Filer)_ex321q32023\n",
      "0231031transactionCoding: transactionFormType: 4transactionCode: JequitySwapInvolved: 0transactionAmounts: transactionShares: value: 7225434transactionPricePerShare: value: 0transactionAcquiredDisposedCode: value: DpostTransactionAmounts: sharesOwnedFollowingTransaction: value: 39279509ownershipNature: directOrIndirectOwnership: value: Dfootnotes: footnote: Securities disposed represent the forfeiture of unvested restricted Class I shares of common stock originally granted to the director following his reelection to the Issuer's board of directors on September 20, 2023 The award was rescinded by the Issuer on October 31, 2023 as a result of the director's resignation from the board, effective as of November 1, 2023footnote: Amount of securities beneficially \n",
      "4 - Cabanas Humberto (0001669525) (Reporting)_wk-form4_1698854883\n",
      "on Capital IV GP Limited, which is the General Partner of each of the Funds The Funds are the owners of BridgeCo and Lion FIV PledgeCo Limited, the latter of which is the General Partner of PledgeCo The Funds and BridgeCo are limited partners of PledgeCo The Manager is controlled by Lyndon Lea As a result, Lyndon Lea may be deemed to beneficially own the reported securitiesfootnote: Each of PledgeCo, BridgeCo, Lion Capital IV GP Limited, the Manager and Lyndon Lea disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein and the filing of this statement shall not be deemed an admission that such person is the beneficial owner of the reported securities for the purposes of Section 16 of the Exchange Act \n",
      "4 - Lion Capital LLP (0001459120) (Reporting)_ownership\n",
      "xplicitMember: srt:MaximumMemberexplicitMember: srzn:PIPEWarrantsMemberperiod: startDate: 20230101endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: srzn:PIPEWarrantsMemberexplicitMember: usgaap:FairValueInputsLevel1MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893period: startDate: 20220101endDate: 20220331context: entity: identifier: 0001824893segment: explicitMember: usgaap:AdditionalPaidInCapitalMemberperiod: instant: 20211231context: entity: identifier: 0001824893segment: explicitMember: usgaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberexplicitMember: usgaap:FairValueInputsLevel3MemberexplicitMember: usgaap:FairValueMeasurementsRecurrin\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      " 6th Floorcity: New YorkstateOrCountry: NYzipCode: 10017noOfUnitsSold: 10000aggregateMarketValue: 740000noOfUnitsOutstanding: 23898757approxSaleDate: 11/28/2023securitiesExchangeName: NASDAQsecuritiesToBeSold: securitiesClassTitle: Class A CommonacquiredDate: 11/28/2023natureOfAcquisitionTransaction: Class A Common Shares received in exchange of Class B Units The Class B Units were acquired on May 1, 2018nameOfPersonfromWhomAcquired: IssuerisGiftTransaction: NamountOfSecuritiesAcquired: 10000paymentDate: 11/28/2023natureOfPayment: N/AnothingToReportFlagOnSecuritiesSoldInPast3Months: NsecuritiesSoldInPast3Months: sellerDetails: name: Lindy Jean Langstonaddress: street1: C/o Goosehead Insurance, Incstreet2: 1500 Solana Blvd, Bldg 4, Suite 4500city: Westlakesta\n",
      "144 - Lindy Langston Spousal Lifetime Access Trust (0001850722) (Reporting)_primary_doc\n",
      "rehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberperiod: instant: 20220630context: entity: identifier: 0001824893segment: explicitMember: srzn:PIPEWarrantsMemberexplicitMember: usgaap:FairValueInputsLevel3MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:AdditionalPaidInCapitalMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:AdditionalPaidInCapitalMemberperiod: instant: 20220930context: entity: identifier: 0001824893segment: explicitMember: usgaap:MoneyMarketFundsMemberexplicitMember: usgaap:FairValueInputsLevel3Memberexplicit\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "tant: 20230930context: entity: identifier: 0001824893segment: explicitMember: srzn:PublicWarrantsMemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20230930context: entity: identifier: 0001824893period: instant: 20220331context: entity: identifier: 0001824893segment: explicitMember: usgaap:GeneralAndAdministrativeExpenseMemberperiod: startDate: 20220701endDate: 20220930context: entity: identifier: 0001824893segment: explicitMember: srzn:PIPEWarrantsMemberexplicitMember: usgaap:FairValueInputsLevel1MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExclude\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "daily Long COVID r elated pain intensity score 4 and 9 Post COVID 19 Functional Status (PCFS) scale score of at Screening & Baseline Willing and able to withdraw from: approved FM drugs, opioids, tramadol, tapentadol, tricyclics, trazodone, orexin receptor antagonists, benzodiazepines 7 2023 Tonix Pharmaceuticals Holding Corp CNS PORTFOLIO Demographics and Baseline Characteristics 1 Tonix Press Release, September 5, 2023 https://bitly/3Z6FQHQ Variable Placebo TNX102 SL Total N=31 N=32 N=63 Age, mean years (SD) 514 (1001) 486 (880) 500 (945) Female, number (%) 25 (806%) 21 (656%) 46 (730%) Male, number (%) 6 (194%) 11 (344%) 17 (270%) Ethnicity Hispanic or Latino 3 (97%) 2 (63%) 5 (79%) Not Hispanic or Latino 28 (806%) 30 (938%) 58 (921%) Race American Indian\n",
      "8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)_ex99_03\n",
      "ualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberperiod: startDate: 20230401endDate: 20230630context: entity: identifier: 0001824893segment: explicitMember: usgaap:FairValueInputsLevel1MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: srzn:ClosingSalePriceBelow1200PerShareMemberperiod: instant: 20220228context: entity: identifier: 0001824893segment: explicitMember: srzn:GovernmentBondsMemberexplicitMember: usgaap:FairValueInputsLevel3MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: srzn:DistributedBioSubscriptio\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "rComprehensiveIncomeLossNetOfTax: 52000OtherComprehensiveIncomeLossNetOfTax: 52000ProfitLoss: 13357000ProfitLoss: 13357000SharesIssued: 35123000StockholdersEquity: 4000StockholdersEquity: 255789000StockholdersEquity: 424000StockholdersEquity: 177878000StockholdersEquity: 77491000ProfitLoss: 34129000ProfitLoss: 35229000DepreciationAndAmortization: 1460000DepreciationAndAmortization: 1477000ShareBasedCompensation: 3200000ShareBasedCompensation: 2972000OperatingLeaseRightOfUseAssetAmortizationExpense: 937000OperatingLeaseRightOfUseAssetAmortizationExpense: 1024000AmortizationOfDebtDiscountPremium: 688000AmortizationOfDebtDiscountPremium: 270000FairValueAdjustmentOfWarrants: 83000FairValueAdjustmentOfWarrants: 6969000IssuanceOfCommonStockAsACommitmentFeeUnderEqu\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "ueAdjustmentOfWarrants: 6969000IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement: 0IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement: 273000IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets: 955000IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets: 885000IncreaseDecreaseInOtherOperatingCapitalNet: 38000IncreaseDecreaseInOtherOperatingCapitalNet: 398000IncreaseDecreaseInAccountsPayable: 371000IncreaseDecreaseInAccountsPayable: 2365000IncreaseDecreaseInAccruedLiabilities: 2728000IncreaseDecreaseInAccruedLiabilities: 2433000IncreaseDecreaseInOperatingLeaseLiability: 1643000IncreaseDecreaseInOperatingLeaseLiability: 1677000NetCashProvidedByUsedInOperatingActivities: 33052000NetCashProvidedByUsedInOperatingActivities: 4394\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      " the reported securities for the purposes of Section 16 of the Exchange Act or otherwiseownerSignature: signatureName: Lion Capital LLP, /s/ Lyndon Lea, its Managing PartnersignatureDate: 20231027ownerSignature: signatureName: Lion Capital IV GP Limited, /s/ Graham Tester, its DirectorsignatureDate: 20231027ownerSignature: signatureName: Lyndon Lea, /s/ Lyndon LeasignatureDate: 20231027\n",
      "4 - Lion Capital LLP (0001459120) (Reporting)_ownership\n",
      "s: 42170000InvestmentIncomeInterest: 661000InvestmentIncomeInterest: 198000InvestmentIncomeInterest: 1831000InvestmentIncomeInterest: 307000OtherNonoperatingIncomeExpense: 83000OtherNonoperatingIncomeExpense: 50000OtherNonoperatingIncomeExpense: 96000OtherNonoperatingIncomeExpense: 6634000NetIncomeLoss: 10445000NetIncomeLoss: 13357000NetIncomeLoss: 34129000NetIncomeLoss: 35229000UnrealizedGainLossOnInvestments: 4000UnrealizedGainLossOnInvestments: 52000UnrealizedGainLossOnInvestments: 242000UnrealizedGainLossOnInvestments: 305000ComprehensiveIncomeNetOfTax: 10449000ComprehensiveIncomeNetOfTax: 13305000ComprehensiveIncomeNetOfTax: 33887000ComprehensiveIncomeNetOfTax: 35534000EarningsPerShareBasic: 0.34EarningsPerShareDiluted: 0.34EarningsPerShareBasic: 0.38Ea\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "ï»¿edgarSubmission: headerData: submissionType: 144filerInfo: filer: filerCredentials: cik: 0001850722ccc: XXXXXXXXliveTestFlag: LIVEformData: issuerInfo: issuerCik: 0001726978issuerName: Goosehead Insurance, IncsecFileNumber: 00138466issuerAddress: street1: 1500 SOLANA BLVDstreet2: BUILDING 4, SUITE 4500city: WESTLAKEstateOrCountry: TXzipCode: 76262issuerContactPhone: 2148385500nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold: Lindy Langston Spousal Lifetime Access TrustrelationshipsToIssuer: relationshipToIssuer: AffiliatesecuritiesInformation: securitiesClassTitle: Class A CommonbrokerOrMarketmakerDetails: name: JP Morgan Securities LLCaddress: street1: 390 Madison Avenuestreet2: 6th Floorcity: New YorkstateOrCountry: NYzipCode: 10017noOfUnitsSold: 10000\n",
      "144 - Lindy Langston Spousal Lifetime Access Trust (0001850722) (Reporting)_primary_doc\n",
      "r: usgaap:FairValueInputsLevel1MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893period: instant: 20211231context: entity: identifier: 0001824893segment: explicitMember: usgaap:CommonStockMemberperiod: startDate: 20220401endDate: 20220630context: entity: identifier: 0001824893segment: explicitMember: usgaap:CommonStockMemberperiod: instant: 20211231context: entity: identifier: 0001824893segment: explicitMember: srzn:PIPEWarrantsMemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPort\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "ndDate: 20160331context: entity: identifier: 0001824893segment: explicitMember: usgaap:MoneyMarketFundsMemberexplicitMember: usgaap:FairValueInputsLevel2MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:RetainedEarningsMemberperiod: instant: 20220331context: entity: identifier: 0001824893segment: explicitMember: srzn:DistributedBioSubscriptionAgreementMemberperiod: startDate: 20220701endDate: 20220930context: entity: identifier: 0001824893segment: explicitMember: usgaap:RetainedEarningsMemberperiod: startDate: 20220701endDate: 20220930unit: measure: pureunit: measure: utr:sqftunit: measure: sharesunit: divide: unitNumerator: measure: iso4217:USDunit\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "context: entity: identifier: 0001824893segment: explicitMember: usgaap:RestrictedStockUnitsRSUMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:CommercialPaperMemberexplicitMember: usgaap:FairValueInputsLevel2MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:CommonStockMemberperiod: startDate: 20230701endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: srzn:CorporateBondMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAt\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "ding: transactionFormType: 4transactionCode: SequitySwapInvolved: 0transactionAmounts: transactionShares: value: 152041transactionPricePerShare: value: 79925transactionAcquiredDisposedCode: value: DpostTransactionAmounts: sharesOwnedFollowingTransaction: value: 157857ownershipNature: directOrIndirectOwnership: value: Dfootnotes: footnote: The reported transactions were executed in multiple trades The sale price of $79925 reported in Column 4 is the weighted average sale price for the 152,041 shares disposed of by the Reporting Person within a range of $800 to $799 per share The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares d\n",
      "4 - SoFi Technologies, Inc. (0001818874) (Issuer)_wk-form4_1699316590\n",
      "ï»¿ EX321 4 ex321q32023htm EX321 Document EXHIBIT 321 CERTIFICATION PURSUANT TO 18 USC SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANESOXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10Q of The Brinks Company (the Company) for the period endedSeptember30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Mark Eubanks, President and Chief Executive Officer of the Company, certify, pursuant to 18 USC 1350, as adopted pursuant to 906 of the SarbanesOxley Act of 2002, that: (1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2)the information contained in the Report fairly presents, in all material respects, the financ\n",
      "10-Q - BRINKS CO (0000078890) (Filer)_ex321q32023\n",
      "OLIO Patient Global Impression of Change Responder Analysis ( Much or Very Much Improved) 1 1 Tonix Press Release, September 5, 2023 https://bitly/3Z6FQHQ 129% 97% 129% 161% 94% 313% 281% 344% 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50% Week 2 Week 6 Week 10 Week 14 Study Week Patient Global Impression of Change (PGIC) Responder Analysis Placebo (N=31) TNX102 SL 56 mg (N=32) Percent 'Much Improved' or 'Very Much Improved' * # *p=0034, # p= 0096 15 2023 Tonix Pharmaceuticals Holding Corp CNS PORTFOLIO Safety and Most Common Adverse Events 1 1 Tonix Press Release, September 5, 2023 https://bitly/3Z6FQHQ Placebo TNX102 SL Total N=31 N=32 N=63 Administration Site Reactions Hypoaesthesia oral 0 6 6 Product taste abnormal 0 3 3 Glossodynia 0 2 2 Oral pain 0 2 2 Para\n",
      "8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)_ex99_03\n",
      "te: 20230331context: entity: identifier: 0001824893segment: explicitMember: usgaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberperiod: instant: 20220331context: entity: identifier: 0001824893segment: explicitMember: srzn:EmployeeSeveranceAndOtherBenefitsMemberperiod: startDate: 20230401endDate: 20230630context: entity: identifier: 0001824893segment: explicitMember: usgaap:RetainedEarningsMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:CommercialPaperMemberexplicitMember: usgaap:FairValueInputsLevel3MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identi\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "tLoss: 10445000SharesIssued: 30575000StockholdersEquity: 3000StockholdersEquity: 258309000StockholdersEquity: 1000StockholdersEquity: 212782000StockholdersEquity: 45531000SharesIssued: 35034000StockholdersEquity: 4000StockholdersEquity: 252464000StockholdersEquity: 119000StockholdersEquity: 142649000StockholdersEquity: 109700000IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreementShares: 100000IssuanceOfCommonStockUnderEquityPurchaseAgreement: 273IssuanceOfCommonStockUnderEquityPurchaseAgreement: 273RepurchaseOfEarlyExercisedStockOptionsShares: 8000RepurchaseOfEarlyExcercisedStockOptions: 0AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue: 30000AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue: 30000StockIssued\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "19 $ 21 Government bonds 3 17,802 221 Total 7 $ 27,521 $ 242 DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions: 4DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months: 9719000DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss: 21000DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions: 3DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months: 17802000DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss: 221000DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions: 7DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months: 27521000DebtSecuritiesAvailableForS\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "nstant: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:CommonStockMemberperiod: startDate: 20230401endDate: 20230630context: entity: identifier: 0001824893segment: explicitMember: usgaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberperiod: startDate: 20230701endDate: 20230930context: entity: identifier: 0001824893period: instant: 20220630context: entity: identifier: 0001824893segment: explicitMember: usgaap:AccountsReceivableMemberexplicitMember: srzn:CollaborationAndLicenseAgreementWithBiMemberperiod: startDate: 20220101endDate: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:MoneyMarketFundsMemberexp\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      " Stilwell Partners, LP ('SP') and indirectly by Joseph Stilwell in his capacity as the managing member and owner of Value, which is the general partner of SP Joseph Stilwell disclaims beneficial ownership of all shares reported as owned indirectly except to the extent of his pecuniary interest thereinremarks: The reporting persons are jointly filing this statement as members of a Section 13(d) group that beneficially owns more than 10% of the issuer's common stockownerSignature: signatureName: /s/ Joseph StilwellsignatureDate: 20230908ownerSignature: signatureName: /s/ Joseph Stilwell as authorized agent for Stilwell Value LLCsignatureDate: 20230908ownerSignature: signatureName: /s/ Joseph Stilwell as authorized agent for Stilwell Activist Fund, LPsignatureD\n",
      "4 - Stilwell Value LLC (0001397076) (Reporting)_tm2325769-1_4seq1\n",
      " CS symptoms ( CSI 2 40/100) 65% of Long COVID participants had severe CS symptoms Prevalence of CS in Long COVID patients 28 2023 Tonix Pharmaceuticals Holding Corp CNS PORTFOLIO Long COVID Patients in TriNetX Study 1 Retrospective Observational Database Study 1 Harris, H, et al Tonix data on file 2022 2 TriNetX Analytics 3 Topaloglu, U, and Palchuk , MB JCO clinical cancer informatics 2018;2:1 10 TriNetX Dataworks USA Network 2: A federated network of inpatient and outpatient electronic medical records from 48 US healthcare organizations (HCOs) The platform returns aggregated patient counts and results from HCOs having patients meeting the study selection criteria Claims data based on diagnostic codes used by practitioners Case numbers may underestimate ac\n",
      "8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)_ex99_03\n",
      "effective as of November 1, 2023footnote: Amount of securities beneficially owned includes both Class AX and Class I shares of common stockownerSignature: signatureName: /s/ J Shea Morgenroth, by power of attorneysignatureDate: 20231101\n",
      "4 - Cabanas Humberto (0001669525) (Reporting)_wk-form4_1698854883\n",
      "alue: 25599ownershipNature: directOrIndirectOwnership: value: DnonDerivativeTransaction: securityTitle: value: Common StocktransactionDate: value: 20231013transactionCoding: transactionFormType: 4transactionCode: MequitySwapInvolved: 0transactionTimeliness: transactionAmounts: transactionShares: value: 1684transactionPricePerShare: transactionAcquiredDisposedCode: value: ApostTransactionAmounts: sharesOwnedFollowingTransaction: value: 27283ownershipNature: directOrIndirectOwnership: value: DnonDerivativeTransaction: securityTitle: value: Common StocktransactionDate: value: 20231013transactionCoding: transactionFormType: 4transactionCode: FequitySwapInvolved: 0transactionTimeliness: transactionAmounts: transactionShares: value: 747transactionPricePerShare: va\n",
      "4 - Giljum Matthew C. (0001809723) (Reporting)_doc4\n",
      "701endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: srzn:TwoThousandTwentyOneStockPlanMemberexplicitMember: usgaap:EmployeeStockMemberperiod: startDate: 20230101endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:EmployeeStockOptionMemberperiod: startDate: 20230101endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: srzn:StanfordMemberexplicitMember: srzn:StanfordLicenseAgreementsMemberperiod: startDate: 20180601endDate: 20180630context: entity: identifier: 0001824893segment: explicitMember: srzn:StanfordMemberexplicitMember: srzn:StanfordLicenseAgreementsMemberperiod: startDate: 20160301endDate: 20160331context: entity: identifier: 0001824893segment: explicitMemb\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      " on diagnostic codes used by practitioners Case numbers may underestimate actual incidence due to underreporting or miscoding Over 50,000 Long COVID patients were identified for the study 1 3 52,322 260,082 931,837 47 47 45 48 47 75,241,815 1,004,258 HCOs Patients Network COVID diagnosis (PCR+) and Age 18 65 Cannot have other specified viral infection At least 1 encounter 180 days post index Long COVID symptoms days 91 180 PCR = Polymerase Chain Reaction Encounter = Interaction with healthcare provider in network 29 2023 Tonix Pharmaceuticals Holding Corp CNS PORTFOLIO L ong COVID P atients in T riNetX study 1 F ibromyalgia like Symptoms (Multi Site Pain) in Over 40% of Patients 1,2 79% 13% 6% 2% 52,322 total Long COVID patients 21,694 total FM like Long COV\n",
      "8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)_ex99_03\n",
      "20230907transactionCoding: transactionFormType: 4transactionCode: PequitySwapInvolved: 0transactionAmounts: transactionShares: value: 5000transactionPricePerShare: value: 99683transactionAcquiredDisposedCode: value: ApostTransactionAmounts: sharesOwnedFollowingTransaction: value: 1458696ownershipNature: directOrIndirectOwnership: value: InatureOfOwnership: value: See footnotenonDerivativeHolding: securityTitle: value: Common StockpostTransactionAmounts: sharesOwnedFollowingTransaction: value: 50000ownershipNature: directOrIndirectOwnership: value: InatureOfOwnership: value: See footnotefootnotes: footnote: These shares are owned directly by Stilwell Activist Fund, LP ('SAF') and indirectly by Joseph Stilwell in his capacity as the managing member and owner o\n",
      "4 - Stilwell Value LLC (0001397076) (Reporting)_tm2325769-1_4seq1\n",
      "30context: entity: identifier: 0001824893segment: explicitMember: srt:MaximumMemberexplicitMember: srzn:StanfordMemberexplicitMember: srzn:StanfordLicenseAgreementsMemberperiod: startDate: 20160301endDate: 20160331context: entity: identifier: 0001824893segment: explicitMember: usgaap:GeneralAndAdministrativeExpenseMemberperiod: startDate: 20220101endDate: 20220930context: entity: identifier: 0001824893segment: explicitMember: srzn:PIPEWarrantsMemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: srzn:RestrictedStockAwardRSAMemberperiod: startDate: 20230101endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: srzn:UnvestedCommonStockS\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "nerState: X0rptOwnerZipCode: SW1X 7HFrptOwnerStateDescription: UNITED KINGDOMreportingOwnerRelationship: isDirector: falseisOfficer: falseisTenPercentOwner: trueisOther: falsereportingOwner: reportingOwnerId: rptOwnerCik: 0001459118rptOwnerName: Lea LyndonreportingOwnerAddress: rptOwnerStreet1: 21 GROSVENOR PLACErptOwnerCity: LONDONrptOwnerState: X0rptOwnerZipCode: SW1X 7HFrptOwnerStateDescription: UNITED KINGDOMreportingOwnerRelationship: isDirector: trueisOfficer: falseisTenPercentOwner: falseisOther: falseaff10b5One: falsederivativeTable: derivativeTransaction: securityTitle: value: Series B Convertible Preferred StockconversionOrExercisePrice: transactionDate: value: 20230329transactionCoding: transactionFormType: 4transactionCode: PequitySwapInvolved: f\n",
      "4 - Lion Capital LLP (0001459120) (Reporting)_ownership\n",
      "PreCommencementIssuerTenderOffer: falseEntityEmergingGrowthCompany: false\n",
      "8-K - Kosmos Energy Ltd. (0001509991) (Filer)_kos-20231106_htm\n",
      "ï»¿xbrl: context: entity: identifier: 0001923622period: startDate: 20231030endDate: 20231030unit: measure: iso4217:USDunit: measure: sharesunit: divide: unitNumerator: measure: iso4217:USDunitDenominator: measure: sharesEntityCentralIndexKey: 0001923622AmendmentFlag: falseDocumentType: 8KDocumentPeriodEndDate: 20231030EntityRegistrantName: PGIM Private Credit FundEntityIncorporationStateCountryCode: DEEntityFileNumber: 81401582EntityTaxIdentificationNumber: 881771414EntityAddressAddressLine1: 655 Broad StreetEntityAddressCityOrTown: NewarkEntityAddressStateOrProvince: NJEntityAddressPostalZipCode: 071024410CityAreaCode: 973LocalPhoneNumber: 8025032WrittenCommunications: falseSolicitingMaterial: falsePreCommencementTenderOffer: falsePreCommencementIssuerTenderO\n",
      "8-K - PGIM Private Credit Fund (0001923622) (Filer)_tm2326215d1_8k_htm\n",
      "ï»¿ownershipDocument: schemaVersion: X0508documentType: 4periodOfReport: 20230329issuer: issuerCik: 0001725134issuerName: Digital Media Solutions, IncissuerTradingSymbol: DMSreportingOwner: reportingOwnerId: rptOwnerCik: 0001459120rptOwnerName: Lion Capital LLPreportingOwnerAddress: rptOwnerStreet1: 21 GROSVENOR PLACErptOwnerCity: LONDONrptOwnerState: X0rptOwnerZipCode: SW1X 7HFrptOwnerStateDescription: UNITED KINGDOMreportingOwnerRelationship: isDirector: trueisOfficer: falseisTenPercentOwner: trueisOther: falsereportingOwner: reportingOwnerId: rptOwnerCik: 0001818065rptOwnerName: LION CAPITAL IV GP LtdreportingOwnerAddress: rptOwnerStreet1: 21 GROSVENOR PLACErptOwnerCity: LONDONrptOwnerState: X0rptOwnerZipCode: SW1X 7HFrptOwnerStateDescription: UNITED KINGDO\n",
      "4 - Lion Capital LLP (0001459120) (Reporting)_ownership\n",
      "ier: 0001824893segment: explicitMember: srzn:PIPEWarrantsMemberexplicitMember: usgaap:FairValueInputsLevel2MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:CommonStockMemberperiod: instant: 20220630context: entity: identifier: 0001824893segment: explicitMember: srzn:LincolnParkMemberperiod: startDate: 20230101endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: srt:MinimumMemberexplicitMember: srzn:LincolnParkMemberperiod: startDate: 20220201endDate: 20220228context: entity: identifier: 0001824893segment: explicitMember: srzn:RestrictedStockAwardRSAMemberperiod: startDate: 20230101endDate: 20230930context: entity: identi\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      ": entity: identifier: 0001824893segment: explicitMember: usgaap:FairValueInputsLevel1MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:StockOptionMemberperiod: startDate: 20230101endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberperiod: startDate: 20220101endDate: 20220331context: entity: identifier: 0001824893segment: explicitMember: srzn:TwoThousandTwentyOneStockPlanMemberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:Restr\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "siveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: srt:MaximumMemberexplicitMember: srzn:LincolnParkMemberperiod: startDate: 20220201endDate: 20220228context: entity: identifier: 0001824893segment: explicitMember: srzn:EmployeeStockPurchasePlanMemberperiod: startDate: 20230101endDate: 20230930context: entity: identifier: 0001824893period: startDate: 20230101endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: srzn:UnvestedCommonStockSharesSubjectToRepurchaseMemberperiod: startDate: 20220101endDate: 20220930context: entity: identifier: 0001824893segment: explicitMember: srt:Maximu\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "ï»¿ownershipDocument: schemaVersion: X0508documentType: 4periodOfReport: 20230907notSubjectToSection16: 0issuer: issuerCik: 0001778784issuerName: Provident Bancorp, Inc /MD/issuerTradingSymbol: PVBCreportingOwner: reportingOwnerId: rptOwnerCik: 0001113303rptOwnerName: STILWELL JOSEPHreportingOwnerAddress: rptOwnerStreet1: 200 CALLE DEL SANTO CRISTOrptOwnerCity: SAN JUANrptOwnerState: PRrptOwnerZipCode: 00901rptOwnerStateDescription: PUERTO RICOreportingOwnerRelationship: isDirector: 0isOfficer: 0isTenPercentOwner: 1isOther: 0reportingOwner: reportingOwnerId: rptOwnerCik: 0001397076rptOwnerName: Stilwell Value LLCreportingOwnerAddress: rptOwnerStreet1: 111 BROADWAY, 12TH FLOORrptOwnerCity: NEW YORKrptOwnerState: NYrptOwnerZipCode: 10006reportingOwnerRelationshi\n",
      "4 - Stilwell Value LLC (0001397076) (Reporting)_tm2325769-1_4seq1\n",
      "ough thelist as well as move the current view to the correspondinghighlighted fact location automatically When a fact in the FactsResults List is selected, it will reveal the Fact Review Window Certain letters may appear to the rightof an item in the Fact Result list to indicate a certainproperty If the letter 'A' appears for a fact, it indicates thefact is additional data (ie, hidden with potentially nocorresponding HTML presentation) If the letter 'C' appears, thefact is tagged with a custom tag If the letter 'D' appears, thefact is tagged with dimensional information Sections The SECTIONS toolbar item provides alisting of the tagged sections of the Inline document Sectionsare divided into three groups: Document & Entity Information Financial Statements No\n",
      "8-K - NNN REIT, INC. (0000751364) (Filer)_nnn-20231101\n",
      "icitMember: usgaap:FairValueInputsLevel2MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:CommonStockMemberperiod: instant: 20220331context: entity: identifier: 0001824893segment: explicitMember: usgaap:ResearchAndDevelopmentExpenseMemberperiod: startDate: 20220701endDate: 20220930context: entity: identifier: 0001824893segment: explicitMember: srzn:PublicWarrantsMemberexplicitMember: usgaap:FairValueInputsLevel3MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:AdditionalPaidInCapitalMemberperiod: instant: 20220331context: entity: identifier\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "ty: identifier: 0001824893segment: explicitMember: srzn:UnvestedCommonStockSharesSubjectToRepurchaseMemberperiod: startDate: 20230101endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: srzn:GovernmentBondsMemberexplicitMember: usgaap:FairValueInputsLevel3MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:CommercialPaperMemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:StockOptionMemberperiod: startDate: 20220101endDate: 20220930context: entity: identifier: 0001824893segment: explicitMember: usgaap:FairValueMeasur\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "ï»¿ownershipDocument: schemaVersion: X0508documentType: 4periodOfReport: 20230922notSubjectToSection16: 0issuer: issuerCik: 0001968915issuerName: PHINIA INC.issuerTradingSymbol: PHINreportingOwner: reportingOwnerId: rptOwnerCik: 0001983540rptOwnerName: Newton LatondrareportingOwnerAddress: rptOwnerStreet1: 3000 UNIVERSITY DRIVErptOwnerCity: AUBURN HILLSrptOwnerState: MIrptOwnerZipCode: 48326reportingOwnerRelationship: isDirector: 1isOfficer: 0isTenPercentOwner: 0isOther: 0aff10b5One: 0nonDerivativeTable: nonDerivativeTransaction: securityTitle: value: Common StocktransactionDate: value: 20230922transactionCoding: transactionFormType: 4transactionCode: AequitySwapInvolved: 0transactionAmounts: transactionShares: value: 125transactionPricePerShare: value: 0trans\n",
      "4 - Newton Latondra (0001983540) (Reporting)_wk-form4_1695763702\n",
      "tal financial liabilities measured at fair value $ 112 $ 131 $ $ 243 As of December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Money market funds (1) $ 9,194 $ $ $ 9,194 Commercial paper 22,549 22,549 Corporate bonds 10,797 10,797 Government bonds 17,802 17,802 Government agency debt securities (1) 3,982 3,982 Total financial assets measured at fair value $ 9,194 $ 55,130 $ $ 64,324 Liabilities (3) : Public Warrants $ 151 $ $ $ 151 PIPE Warrants 175 175 Total financial liabilities measured at fair value $ 151 $ 175 $ $ 326 (1) I ncluded in cash and cash equivalents on the condensed consolidated balance sheet. (2) C onsists of $ 1.5 million in cash and cash equivalents and $ 1.5 million in shortterm marketable securities. (3) See Note 10. There were no ch\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "usgaap:RetainedEarningsMemberperiod: instant: 20230331context: entity: identifier: 0001824893segment: explicitMember: usgaap:RetainedEarningsMemberperiod: startDate: 20230701endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: srzn:StanfordMemberexplicitMember: srzn:StanfordLicenseAgreementsMemberperiod: startDate: 20230101endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: stpr:CAexplicitMember: srzn:EightYearsMemberperiod: instant: 20160831context: entity: identifier: 0001824893segment: explicitMember: usgaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberperiod: instant: 20211231context: entity: identifier:\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting Date: November 7, 2023 /s/ York A Ragen Name: York A Ragen Title: Chief Financial Officer\n",
      "10-Q - GENERAC HOLDINGS INC. (0001474735) (Filer)_ex_563898\n",
      "o: 891000LesseeOperatingLeaseLiabilityPaymentsDue: 4217000LesseeOperatingLeaseLiabilityUndiscountedExcessAmount: 258000OperatingLeaseLiability: 3959000StockholdersEquityNoteDisclosureTextBlock: Note 9. Stockholders Equity Equity Purchase Agreement In February 2022, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park, or the Equity Purchase Agreement, pursuant to which Lincoln Park is obligated to purchase up to $ 50.0 million shares of the Companys common stock. Upon execution of the Equity Purchase Agreement, the Company issued 0.1 million shares of common stock to Lincoln Park with the fair value of $ 0.3 million as consideration for Lincoln Parks commitment to purchase the Companys common stock, which was inc\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "ï»¿xbrl: context: entity: identifier: 0000052827period: startDate: 20231101endDate: 20231101context: entity: identifier: 0000052827segment: explicitMember: ryn:RayonierLimitedPartnershipMemberperiod: startDate: 20231101endDate: 20231101EntityCentralIndexKey: 0000052827EntityCentralIndexKey: 0001806931AmendmentFlag: falseDocumentType: 8KDocumentPeriodEndDate: 20231101EntityFileNumber: 16780EntityFileNumber: 333237246EntityRegistrantName: RAYONIER INCEntityIncorporationStateCountryCode: NCEntityTaxIdentificationNumber: 132607329EntityRegistrantName: RAYONIER, L.P.EntityIncorporationStateCountryCode: DEEntityTaxIdentificationNumber: 911313292EntityAddressAddressLine1: 1 Rayonier WayEntityAddressAddressLine1: 1 Rayonier WayEntityAddressCityOrTown: WildlightEntityA\n",
      "8-K - RAYONIER INC (0000052827) (Filer)_ryn-20231101_htm\n",
      "rectly by Joseph Stilwell in his capacity as the managing member and owner of Stilwell Value LLC ('Value'), which is the general partner of SAF Joseph Stilwell disclaims beneficial ownership of all shares reported as owned indirectly except to the extent of his pecuniary interest thereinfootnote: These shares are owned directly by Stilwell Activist Investments, LP ('SAI') and indirectly by Joseph Stilwell in his capacity as the managing member and owner of Value, which is the general partner of SAI Joseph Stilwell disclaims beneficial ownership of all shares reported as owned indirectly except to the extent of his pecuniary interest thereinfootnote: These shares are owned directly by Stilwell Partners, LP ('SP') and indirectly by Joseph Stilwell in his capac\n",
      "4 - Stilwell Value LLC (0001397076) (Reporting)_tm2325769-1_4seq1\n",
      "eMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: srzn:PIPEWarrantsMemberperiod: startDate: 20230101endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: srzn:CorporateBondMemberexplicitMember: usgaap:FairValueInputsLevel3MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: srt:MaximumMemberexplicitMember: srzn:PIPEWarrantsMemberperio\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "ep quality scores for TN X 102 SL versus placebo; M ixed Model for Repeated Measures (MMRM), Abbreviations: LS, least squares; SE, standard error 3 Pre specified secondary endpoint, at week 14 (effect size (ES) = 023 26 24 22 2 18 16 14 12 1 08 06 04 02 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 LS Mean Difference (SE) in NRS Sleep Quality Study Week Daily Diary Sleep Quality Ratings Change from Baseline for TNX 102 SL versus Placebo Placebo (N=31) TNX102 SL (N=32) 11 2023 Tonix Pharmaceuticals Holding Corp CNS PORTFOLIO PROMIS Sleep Disturbance 1,2 1 Tonix Press Release, September 5, 2023 https://bitly/3Z6FQHQ 2 Mixed Model for Repeated Measures (MMRM), Abbreviations: LS, least squares; SE, standard error; SD, sleep disturbance 12 10 8 6 4 2 0 Week 0 Week 2 Week \n",
      "8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)_ex99_03\n",
      "ï»¿ownershipDocument: schemaVersion: X0508documentType: 4periodOfReport: 20231031notSubjectToSection16: 1issuer: issuerCik: 0001585101issuerName: HINES GLOBAL INCOME TRUST, INCissuerTradingSymbol: N/AreportingOwner: reportingOwnerId: rptOwnerCik: 0001669525rptOwnerName: Cabanas HumbertoreportingOwnerAddress: rptOwnerStreet1: 845 TEXAS AVENUErptOwnerStreet2: SUITE 3300rptOwnerCity: HOUSTONrptOwnerState: TXrptOwnerZipCode: 77002reportingOwnerRelationship: isDirector: 1isOfficer: 0isTenPercentOwner: 0isOther: 0aff10b5One: 0nonDerivativeTable: nonDerivativeTransaction: securityTitle: value: Common Stock, par value $0001 per sharetransactionDate: value: 20231031deemedExecutionDate: value: 20231031transactionCoding: transactionFormType: 4transactionCode: JequitySwap\n",
      "4 - Cabanas Humberto (0001669525) (Reporting)_wk-form4_1698854883\n",
      "E, standard error; SD, sleep disturbance 12 10 8 6 4 2 0 Week 0 Week 2 Week 6 Week 10 Week 14 LS Mean Difference (SE) in PROMIS SD Study Week PROMIS Sleep Disturbance Change from Baseline for TNX 102 SL versus Placebo Placebo (N=31) TNX102 SL 28 mg (N=32) *p=0028 * 12 2023 Tonix Pharmaceuticals Holding Corp CNS PORTFOLIO PROMIS Fatigue Score 1 5 1 Tonix Press Release, September 5, 2023 https://bitly/3Z6FQHQ 2 Mixed Model for Repeated Measures (MMRM), Abbreviations: LS, least squares; SE, standard error 3 Cook, KF, et al 2016 Journal of Clinical Epidemiology , 73, 89 102 4 Cella, D, et al 2016 Journal of Clinical Epidemiology , 73, 128 134 5 Lai, JS, et al 2011 Archives of Physical Medicine and Rehabilitation , 92(10 Supplement), S20 S27 10 8 6 4 2 0 Week 0 W\n",
      "8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)_ex99_03\n",
      "alueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:ResearchAndDevelopmentExpenseMemberperiod: startDate: 20230101endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: srzn:CorporateBondMemberexplicitMember: usgaap:FairValueInputsLevel2MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: srzn:StanfordLicenseAgreementsMemberperiod: startDate: 20220101endDate: 20220930context: entity: identifier: 0001824893segment: explicitMember: usgaap:CommonStockMemberperiod: startDate: 20230101endDate: 20230331context: entity: identifier: 0001824893segment: explicitMember: \n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "79% 13% 6% 2% 52,322 total Long COVID patients 21,694 total FM like Long COVID patients 1 Harris, H, et al Tonix data on file 2022 2 TriNetX Analytics 59% 41% Multi site pain Multi site pain No multi site pain Multi site pain only Multi site pain and fatigue Multi site pain and insomnia Multi site pain, fatigue, and insomnia 30 2023 Tonix Pharmaceuticals Holding Corp CNS PORTFOLIO L ong COVID Patients in TriNetX Study 1 Recorded Medication Use, Days 91 180 150% 188% 398% 288% 340% 299% 259% 390% 358% 358% 501% 592% 431% 511% 628% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Patients with compounding nociplastic symptoms are medicating with opioids, antidepressants and anxiolytics at higher rates than those with only multi site pain or without pain 1 2 1 Harri\n",
      "8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)_ex99_03\n",
      "Tonix Press Release, September 5, 2023 https://bitly/3Z6FQHQ 2 Walker S, et al BMJ Open 2023;13:e069217 doi:101136/ bmjopen 2022 069217 3 Cook, KF, et al 2016 Journal of Clinical Epidemiology , 73, 89 102 4 Cella, D, et al 2016 Journal of Clinical Epidemiology , 73, 128 134 5 Lai, JS, et al 2011 Archives of Physical Medicine and Rehabilitation , 92(10 Supplement), S20 S27 9 2023 Tonix Pharmaceuticals Holding Corp CNS PORTFOLIO Primary Endpoint: Weekly Summary of Daily Pain Scores 1 3 1 Tonix Press Release, September 5, 2023 https://bitly/3Z6FQHQ 2 Change from baseline in the diary numerical rating scale (NRS) weekly average of daily self reported worst Long COVID pain inten sity scores for TNX 102 SL versus placebo; M ixed Model for Repeated Measures (MMRM),\n",
      "8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)_ex99_03\n",
      "volved: 0transactionAmounts: transactionShares: value: 22973transactionPricePerShare: value: 27.64transactionAcquiredDisposedCode: value: ApostTransactionAmounts: sharesOwnedFollowingTransaction: value: 118078ownershipNature: directOrIndirectOwnership: value: DderivativeTable: derivativeHolding: securityTitle: value: NonQualified Stock Option (right to buy)conversionOrExercisePrice: value: 28.16exerciseDate: value: 20181031expirationDate: value: 20281031underlyingSecurity: underlyingSecurityTitle: value: Common StockunderlyingSecurityShares: value: 618postTransactionAmounts: sharesOwnedFollowingTransaction: value: 618ownershipNature: directOrIndirectOwnership: value: Dfootnotes: footnote: Restricted and performance stock grants vest ratably over three years \n",
      "4 - WAFD INC (0000936528) (Issuer)_wk-form4_1700171914\n",
      "note: Restricted and performance stock grants vest ratably over three years beginning October 31, 2024, respectively, as follows: 9,222 shares, and 13,751 shares based upon certain performance criteria related to total shareholder return.footnote: Includes 57,886 stock units awarded pursuant to a Supplemental Executive Retirement Plan ('SERP') for the benefit of the reporting person.ownerSignature: signatureName: Kelli Holz, AttorneyinfactsignatureDate: 20231116\n",
      "4 - WAFD INC (0000936528) (Issuer)_wk-form4_1700171914\n",
      "ity: 53973000LiabilitiesAndStockholdersEquity: 89435000ResearchAndDevelopmentExpense: 6112000ResearchAndDevelopmentExpense: 8624000ResearchAndDevelopmentExpense: 21135000ResearchAndDevelopmentExpense: 27576000GeneralAndAdministrativeExpense: 3572000GeneralAndAdministrativeExpense: 4981000GeneralAndAdministrativeExpense: 12209000GeneralAndAdministrativeExpense: 14594000RestructuringExpenses: 1505000RestructuringExpenses: 0RestructuringExpenses: 2712000RestructuringExpenses: 0OperatingExpenses: 11189000OperatingExpenses: 13605000OperatingExpenses: 36056000OperatingExpenses: 42170000OperatingIncomeLoss: 11189000OperatingIncomeLoss: 13605000OperatingIncomeLoss: 36056000OperatingIncomeLoss: 42170000InvestmentIncomeInterest: 661000InvestmentIncomeInterest: 198000I\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "2022, the Company used $ 33.1 million and $ 43.9 million of cash in operations, respectively. As of September 30, 2023, the Company had cash, cash equivalents and marketable securities of $ 43.4 million and an accumulated deficit of approximately $ 212.8 million . The Company expects operating expenses to continue to be significant in connection with its ongoing clinical studies and anticipates the need to raise additional capital to continue to execute its longrange business plan. Management believes that the existing cash, cash equivalents and marketable securities are sufficient for the Company to continue operating activities for at least the next 12 months from the date of issuance of its unaudited consolidated financial statements. However, if the Comp\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "tockParOrStatedValuePerShare: 0.0001CommonStockParOrStatedValuePerShare: 0.0001CommonStockSharesAuthorized: 500000000CommonStockSharesAuthorized: 500000000CommonStockSharesIssued: 30575000CommonStockSharesOutstanding: 30575000CommonStockSharesOutstanding: 30088000CommonStockSharesIssued: 30088000CommonStockValue: 3000CommonStockValue: 3000AdditionalPaidInCapital: 258309000AdditionalPaidInCapital: 254892000AccumulatedOtherComprehensiveIncomeLossNetOfTax: 1000AccumulatedOtherComprehensiveIncomeLossNetOfTax: 241000RetainedEarningsAccumulatedDeficit: 212782000RetainedEarningsAccumulatedDeficit: 178653000StockholdersEquity: 45531000StockholdersEquity: 76001000LiabilitiesAndStockholdersEquity: 53973000LiabilitiesAndStockholdersEquity: 89435000ResearchAndDevelopmen\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "ip: isDirector: 0isOfficer: 0isTenPercentOwner: 1isOther: 0reportingOwner: reportingOwnerId: rptOwnerCik: 0001048212rptOwnerName: STILWELL PARTNERS L PreportingOwnerAddress: rptOwnerStreet1: 111 BROADWAY, 12TH FLOORrptOwnerCity: NEW YORKrptOwnerState: NYrptOwnerZipCode: 10006reportingOwnerRelationship: isDirector: 0isOfficer: 0isTenPercentOwner: 1isOther: 0aff10b5One: 0nonDerivativeTable: nonDerivativeHolding: securityTitle: value: Common StockpostTransactionAmounts: sharesOwnedFollowingTransaction: value: 282925ownershipNature: directOrIndirectOwnership: value: InatureOfOwnership: value: See footnotenonDerivativeTransaction: securityTitle: value: Common StocktransactionDate: value: 20230907transactionCoding: transactionFormType: 4transactionCode: PequitySwa\n",
      "4 - Stilwell Value LLC (0001397076) (Reporting)_tm2325769-1_4seq1\n",
      "Material: falsePreCommencementTenderOffer: falsePreCommencementIssuerTenderOffer: falseEntityEmergingGrowthCompany: trueEntityExTransitionPeriod: false\n",
      "8-K - PGIM Private Credit Fund (0001923622) (Filer)_tm2326215d1_8k_htm\n",
      "n 906 has been provided to Public Service Company of Oklahoma and will be retained by Public Service Company of Oklahoma and furnished to the Securities and Exchange Commission or its staff upon request\n",
      "10-Q - AMERICAN ELECTRIC POWER CO INC (0000004904) (Filer)_ex32bpso20233q\n",
      "y replaced the letter of credit issued by SVB with a letter of credit from a different financial institution. The operating lease expense for the three and nine months ended September 30, 2023 and 2022 was $ 0.4 million, $ 1.2 million , $ 0.4 million and $ 1.5 million , respectively. Aggregate future minimum rental payments under the operating leases as of September 30, 2023, were as follows (in thousands): Remaining three months ending December 31, 2023 $ 656 Year ending December 31, 2024 2,670 Year ending December 31, 2025 891 Total lease payments 4,217 Less: Imputed interest ( 258 ) Operating lease liabilities $ 3,959 AreaOfRealEstateProperty: 32813RestrictedNonCurrentCash: 400000OperatingLeaseExpense: 400000OperatingLeaseExpense: 1200000OperatingLeaseExp\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "approved for any indication CNS PORTFOLIO 4 Department of Health and Human Services, Office of the Assistant Secretary for Health 2022 National Research Action Plan on Long COVID Next Steps: End of Phase 2 Meeting with FDA expected 1 st Quarter 2024 6 2023 Tonix Pharmaceuticals Holding Corp CNS PORTFOLIO TNX 102 SL: Phase 2 Study Design Study c haracteristics: Randomized, double blind, placebo controlle d study of TNX 102 SL in fibromyalgia type Long COVID US sites only, completed enrollment of 63 patients Primary Endpoint: Daily diary pain severity score change from baseline to Week 14 (TNX 102 SL vs placebo) Weekly averages of the daily numerical rating scale scores Secondary Endpoints: Change from Baseline in the weekly average of the daily diary NRS asse\n",
      "8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)_ex99_03\n",
      "dentifier: 0001824893segment: explicitMember: srzn:PublicWarrantsMemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:EmployeeStockOptionMemberperiod: startDate: 20220101endDate: 20220930context: entity: identifier: 0001824893segment: explicitMember: srzn:GovernmentBondsMemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:ResearchAndDevelopmentExpenseMemberperiod: startDate: 20220101endDate: 20220930context: entity: identifier: 0001824893segment: explicitMember: srzn:PublicWarrantsMemberperiod: instant: 20230930context: entity: identifier: 000182\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      " 9194000AssetsFairValueDisclosure: 0AssetsFairValueDisclosure: 22549000AssetsFairValueDisclosure: 0AssetsFairValueDisclosure: 22549000AssetsFairValueDisclosure: 0AssetsFairValueDisclosure: 10797000AssetsFairValueDisclosure: 0AssetsFairValueDisclosure: 10797000AssetsFairValueDisclosure: 0AssetsFairValueDisclosure: 17802000AssetsFairValueDisclosure: 0AssetsFairValueDisclosure: 17802000AssetsFairValueDisclosure: 0AssetsFairValueDisclosure: 3982000AssetsFairValueDisclosure: 0AssetsFairValueDisclosure: 3982000AssetsFairValueDisclosure: 9194000AssetsFairValueDisclosure: 55130000AssetsFairValueDisclosure: 0AssetsFairValueDisclosure: 64324000LiabilitiesFairValueDisclosure: 151000LiabilitiesFairValueDisclosure: 0LiabilitiesFairValueDisclosure: 0LiabilitiesFairValueDi\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "3segment: explicitMember: usgaap:GeneralAndAdministrativeExpenseMemberperiod: startDate: 20230701endDate: 20230930context: entity: identifier: 0001824893period: instant: 20220930context: entity: identifier: 0001824893segment: explicitMember: srzn:GovernmentBondsMemberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:CommercialPaperMemberexplicitMember: usgaap:FairValueInputsLevel1MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:AdditionalPaidInCapitalMemberperiod: startDate: 20230101endDate: 20230331context: entity: identifier: 0001824893segment: explicitMember: usgaap:CommonStockMemberperiod: instant: \n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "dentifier: 0001824893segment: explicitMember: srzn:PublicWarrantsMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:CommonStockMemberperiod: startDate: 20220701endDate: 20220930context: entity: identifier: 0001824893segment: explicitMember: srzn:ClosingSalePriceBelow1000PerShareMemberexplicitMember: srzn:LincolnParkMemberperiod: instant: 20220228context: entity: identifier: 0001824893segment: explicitMember: srzn:PublicWarrantsMemberperiod: startDate: 20230101endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:RetainedEarningsMemberperiod: instant: 20220930context: entity: identifier: 0001824893segment: explicitMember: usgaap:USGovernmentCorporationsAndAgenciesSecuritiesMe\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "hallmark of fibromyalgia 2,3 Symptoms of Long COVID, like multi site pain, fatigue, brain fog, and insomnia, are the hallmarks of chronic pain syndromes like fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) In August 2022, the HHS released the National Research Action Plan on Long COVID 4 which endorses the connection between Long COVID and ME/CFS Market Entry : Fibromyalgia Type Long COVID (PASC) Status: Phase 2 study PREVAIL completed Results : Topline data reported 5 Sept 2023 1 J une 22, 2022 CDC https://wwwcdcgov/nchs/pressroom/nchs_press_releases/2022/20220622htm 2 Harris, H, et al Tonix data on file 2022 3 TriNetX Analytics *TNX 102 SL has not been approved for any indication CNS PORTFOLIO 4 Department of Health and Human S\n",
      "8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)_ex99_03\n",
      "ure: 7964000AssetsFairValueDisclosure: 28622000AssetsFairValueDisclosure: 10955000AssetsFairValueDisclosure: 0AssetsFairValueDisclosure: 39577000LiabilitiesFairValueDisclosure: 112000LiabilitiesFairValueDisclosure: 0LiabilitiesFairValueDisclosure: 0LiabilitiesFairValueDisclosure: 112000LiabilitiesFairValueDisclosure: 0LiabilitiesFairValueDisclosure: 131000LiabilitiesFairValueDisclosure: 0LiabilitiesFairValueDisclosure: 131000LiabilitiesFairValueDisclosure: 112000LiabilitiesFairValueDisclosure: 131000LiabilitiesFairValueDisclosure: 0LiabilitiesFairValueDisclosure: 243000AssetsFairValueDisclosure: 9194000AssetsFairValueDisclosure: 0AssetsFairValueDisclosure: 0AssetsFairValueDisclosure: 9194000AssetsFairValueDisclosure: 0AssetsFairValueDisclosure: 22549000Asset\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "P ('PledgeCo'), after giving effect to the October 10, 2023 contribution of such securities to PledgeCo in connection with a financing facility for the benefit of PledgeCo and Lion Capital Fund IV, LP, Lion Capital Fund IVA, LP, Lion Capital Fund IV (USD), LP, Lion Capital Fund IVA (USD), LP, Lion Capital Fund IV SBS, LP and Lion Capital Fund IV SBS (USD), LP (collectively, the 'Funds')footnote: The shares of Series B Convertible Preferred Stock and the Warrants reported on this Form 4 were acquired in a private transaction by Lion Capital (Guernsey) Bridgeco Limited ('BridgeCo') Lion Capital LLP (the 'Manager'), a United Kingdom limited liability partnership, is the sole owner of Lion Capital IV GP Limited, which is the General Partner of each of the Funds \n",
      "4 - Lion Capital LLP (0001459120) (Reporting)_ownership\n",
      "ber: usgaap:FairValueInputsLevel2MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: srzn:RestrictedStockAwardRSAMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: srzn:PIPEWarrantsMemberexplicitMember: usgaap:FairValueInputsLevel3MemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:RetainedEarningsMemberperiod: instant: 20220630context: entity: identifier: 0001824893period: startDate: 20230101endDate: 20230331context: entity: identifier: 0001824893segment: explicitMember: srzn:PIPEWarrantsMemberexplicitMembe\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n",
      "ntifier: 0001824893segment: explicitMember: usgaap:MoneyMarketFundsMemberexplicitMember: usgaap:FairValueMeasurementsRecurringMemberperiod: instant: 20221231context: entity: identifier: 0001824893segment: explicitMember: usgaap:CommonStockMemberperiod: startDate: 20230101endDate: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:StockOptionMemberperiod: startDate: 20220701endDate: 20220930context: entity: identifier: 0001824893segment: explicitMember: srzn:ShortTermMarketableSecuritiesMemberperiod: instant: 20230930context: entity: identifier: 0001824893segment: explicitMember: usgaap:RetainedEarningsMemberperiod: startDate: 20220101endDate: 20220331context: entity: identifier: 0001824893segment: explicitMember: usgaap:MoneyMarke\n",
      "10-Q - Surrozen, Inc._DE (0001824893) (Filer)_srzn-20230930_htm\n"
     ]
    }
   ],
   "source": [
    "results = index.search({'text':'Giljum Matthew C.'})\n",
    "for x in results:\n",
    "    print(x['text'])\n",
    "    print(x['document'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
